Abiopharma

🔍 Morais Mark A. (Executive)

Company: Fortrea Holdings Inc. (FTRE)

Report Date: 2025-08-18

Detailed Transactions and Holdings:

• Acquired 11,312 shares of Common Stock (Direct)
  Date: 2025-08-18 | Code: M | equity_swap_involved: 0 | shares_owned_after: 57,861.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 4,886 shares of Common Stock at $8.01 per share (Direct)
  Date: 2025-08-19 | Code: S | equity_swap_involved: 0 | shares_owned_after: 52,975.00 | transaction_form_type: 4 | Footnotes: F2, F3, F4
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-08-18 | Code: H | nature_of_ownership: Spouse | shares_owned_after: 4,625.00 | Footnotes: F5
• Sold 11,312 shares of Restricted Stock Unit (Derivative)
  Date: 2025-08-18 | Code: M | equity_swap_involved: 0 | shares_owned_after: 88,632.00 | transaction_form_type: 4 | Footnotes: F1, F6, F6, F7

Footnotes:

• F1: Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of Fortrea Holdings Inc. ("Fortrea") Common Stock. This transaction represents the settlement of RSUs into Common Stock on their scheduled vesting date.
• F2: The sales reported on this Form 4 represent shares of Common Stock sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
• F3: This transaction was executed in multiple trades at prices ranging from $7.89 to $8.10. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
• F4: This number reflects the aggregate amount of Common Stock held by the reporting person.
• F5: The balance reflects an indirect interest in 4,625 shares owned by the spouse of the reporting person, whom the reporting person recently married, which were inadvertently omitted from prior filings.
• F6: In connection with the spin-off of Fortrea by Laboratory Corporation of America Holdings ("Labcorp"), RSUs granted by Labcorp were converted into time-vesting RSUs of Fortrea pursuant to the terms of the Employee Matters Agreement. These RSUs vested on August 17, 2025.
• F7: This number reflects the aggregate number of RSUs held by the reporting person.